National

2021

  • To identify epileptogenic foci and seizure propagation neuronal networks through the Janashia-Lagvilava mathematical method among the individuals with pharmacoresistant epilepsy – a pilot study [Projects Principal Investigator Prof. Sofia Kasradze; Sponsor – Caucasus International University, Tbilisi, Georgia].

2022

  • PhD Thesis on “Predictors of outcome in children with infantile spasms syndrome” was prepared and protected [PhD student – A. Kvernadze; Supervisor – Prof. N. Tatishvili].
  • Project: Evaluation of the severity of the burden of epilepsy by quantitative study of health problems caused by the disease in Georgian outpatients [Projects’ Principal Investigator Prof. Sofia Kasradze; Sponsor – Caucasus International University, Tbilisi, Georgia; International supervisor – Prof. Dr. med. S. Noachtar (Munich, Germany)].
  • Project: A study of changes in attitudes and knowledge related to epilepsy in different groups of society after ten years of intervention in Georgia [Projects’ Principal Investigator Ass. Prof. Nino Gogatishvili; Sponsor – Caucasus International University, Tbilisi, Georgia; International supervisor – Prof. GW Sander (London, UK)].

International

  • ECV – Epihunter Clinical Validation – multicentre clinical study to validate a wearable EEG seizure detection solution compared to video EEG in absence seizures.
  • 2001- ongoing – European Registry on Antiepileptic Drugs and Pregnancy (EURAP)
  • 2017- ongoing – Initiating a new national epilepsy surgery program in Georgia [Projects Principal Investigator Prof. Tengis Gloveli; Sponsor – German Federal Ministry of Education and Research, and the German Federal Ministry of Economic Cooperation and Development, Berlin, Germany];
  • UCB EP015; Phase 3B – A multicenter, open-label, follow-up study to assess the long-term use of oral lacosamide in study participants who completed EP0034 or SP848 and recived Lacosamide treatment [Sponsor UCB Biopharma SRL]
  • UCB EP 0132- A multicenter, open-label, Single-arm Study to Evaluate Long term Safety, Tolerability and Efficacy of Brivaracetam in study participants 2- to 26 Years of age with Childhood absence epilepsy or Juvenile Absence Epilepsy [Sponsor UCB Biopharma SRL].